Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.59 |
| ▸ | BRS3 | P32247 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NMBR | P28336 | 2/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743607 | 0.94 | TACR1 (0.59) | TACR1BRS3LMNAMAPTNMBR | |
| SCHEMBL7737679 | 0.93 | TACR1 (0.68) | TACR1BRS3LMNAMAPT | |
| SCHEMBL7745651 | 0.92 | TACR1 (0.58) | TACR1BRS3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7743028 | 0.91 | TACR1 (0.54) | TACR1BRS3MAPTMEN1KMT2A | |
| SCHEMBL7743793 | 0.91 | TACR1 (0.54) | TACR1BRS3MAPTMEN1KMT2A | |
| SCHEMBL7737704 | 0.89 | TACR1 (0.58) | TACR1BRS3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7743621 | 0.88 | TACR1 (0.52) | TACR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7743754 | 0.88 | TACR1 (0.58) | TACR1BRS3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7737730 | 0.87 | TACR1 (0.63) | TACR1NMBR | |
| SCHEMBL7743767 | 0.87 | TACR1 (0.68) | TACR1BRS3LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819005-A4 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | claimed |
| EP-0819005-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | claimed |
| EP-0761220-A1 | 2-Acylaminopropanamides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | claimed |
| WO-1997006803-A1 | 2-ACYLAMINOPROPANAMIDES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| US-5565568-A | USEFUL IN TREATMENT OR PREVENTION OF A PHYSIOLOGICAL DISORDER ASSOCIATED WITH AN EXCESS OF TACHYKININS | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| WO-1996031214-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| EP-0819005-A4 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0819005-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0761220-A1 | 2-Acylaminopropanamides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1997006803-A1 | 2-ACYLAMINOPROPANAMIDES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5565568-A | USEFUL IN TREATMENT OR PREVENTION OF A PHYSIOLOGICAL DISORDER ASSOCIATED WITH AN EXCESS OF TACHYKININS | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996031214-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |